Lyophilization may appear like a gentle drying process, but it comes with significant risks when used with biomolecular reagents in diagnostic tests that are not the same, like the freeze-drying of general pharmaceuticals.
The reagents that are mostly used in PCR and ELISA-based diagnostic kits for conditions like Covid-19, are known to have labile components. These may include enzymes that are necessary to preserve longevity in the supply chain. They may also be vital in preserving the longevity of the antibodies used for testing the patients’ response to the virus. These reagents may not be easy to stabilize when considering commercial use.